Abstract
Purpose of Review: To provide an update on stroke prevention strategies with oral anticoagulants (vitamin K antagonists) and platelet inhibitors. Recent Findings: In asymptomatic women, aspirin reduces the risk of stroke but not of myocardial infarction while in men only the risk of myocardial infarction but not stroke could be significantly reduced. No benefit of oral anticoagulants could be shown in patients with non-cardioembolic stroke. Patients with symptomatic intracranial stenosis had a higher risk of intracerebral bleeding with oral anticoagulation compared to high dose aspirin. The combination of aspirin plus extended-release dipyridamole significantly reduces the risk of recurrent stroke as well as the risk of a combined cardiovascular outcome compared to aspirin alone. The combination of aspirin plus clopidogrel did not reduce the risk of stroke in patients with non-cardioembolic ischemic events compared to clopidogrel monotherapy. Summary: For primary prevention in patients < 65 years without risk factors, no antithrombotic treatment should be given. The choice between oral anticoagulants and antiplatelet agents depends on the stroke etiology and individual risk factor profile. Patients with non-cardioembolic stroke generally are candidates for antiplatelet therapy. New anticoagulation strategies will facilitate dosing and may reduce under-use in patients with atrial fibrillation and clear indications for oral anticoagulation.
Keywords: Stroke, prevention, recurrence, anticoagulation, antiplatelet therapy
Current Drug Therapy
Title: Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Volume: 1 Issue: 3
Author(s): Christian Weimar and Hans-Christoph Diener
Affiliation:
Keywords: Stroke, prevention, recurrence, anticoagulation, antiplatelet therapy
Abstract: Purpose of Review: To provide an update on stroke prevention strategies with oral anticoagulants (vitamin K antagonists) and platelet inhibitors. Recent Findings: In asymptomatic women, aspirin reduces the risk of stroke but not of myocardial infarction while in men only the risk of myocardial infarction but not stroke could be significantly reduced. No benefit of oral anticoagulants could be shown in patients with non-cardioembolic stroke. Patients with symptomatic intracranial stenosis had a higher risk of intracerebral bleeding with oral anticoagulation compared to high dose aspirin. The combination of aspirin plus extended-release dipyridamole significantly reduces the risk of recurrent stroke as well as the risk of a combined cardiovascular outcome compared to aspirin alone. The combination of aspirin plus clopidogrel did not reduce the risk of stroke in patients with non-cardioembolic ischemic events compared to clopidogrel monotherapy. Summary: For primary prevention in patients < 65 years without risk factors, no antithrombotic treatment should be given. The choice between oral anticoagulants and antiplatelet agents depends on the stroke etiology and individual risk factor profile. Patients with non-cardioembolic stroke generally are candidates for antiplatelet therapy. New anticoagulation strategies will facilitate dosing and may reduce under-use in patients with atrial fibrillation and clear indications for oral anticoagulation.
Export Options
About this article
Cite this article as:
Weimar Christian and Diener Hans-Christoph, Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke, Current Drug Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157488506778194965
DOI https://dx.doi.org/10.2174/157488506778194965 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research Magnetomotive Molecular Nanoprobes
Current Medicinal Chemistry Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry Understanding and Modulating the Toll Like Receptors (TLRs) and NOD Like Receptors (NLRs) Cross Talk in Type 2 Diabetes
Current Diabetes Reviews The Location of Vascular Flap is Related with Daily Activity Patterns in Non-traumatic Acute Aortic Syndrome in a Chinese Population
Current Signal Transduction Therapy The Management of Thymoma - A Review of the Status Quo with Practical Treatment Recommendations
Current Respiratory Medicine Reviews Lipoprotein(a) Management: Pharmacological and Apheretic Treatment
Current Medicinal Chemistry Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
Current Medicinal Chemistry Familial Hypercholesterolemia: Etiology, Diagnosis and New Treatment Options
Current Pharmaceutical Design Genetic Studies of Type 2 Diabetes in South Asians: A Systematic Overview
Current Diabetes Reviews Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology